Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07146230 · ClinicalTrials.gov registry record · Phase 2
The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2
A Phase 2 study, sponsored by Montefiore Medical Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT07146230 is a Phase 2 study that has not yet begun recruiting, run by Montefiore Medical Center. The registered enrollment target is 52 participants.
The verdict
NCT07146230, a Phase 2 study, has not yet begun recruiting, sponsored by Montefiore Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
This is a randomized trial evaluating the efficacy and safety of sequential dual-agent immunotherapy and risk-adapted radiotherapy for patients with locally advanced non-small cell lung cancer (NSCLC) with a PD-L1 tumor proportion score of at least 50%. Participants will be randomized between two dual-agent immunotherapy regimens: durvalumab + monalizumab versus durvalumab + oleclumab.
Interventions
- RADIATION Radiotherapy
- DRUG Durvalumab
- DRUG Monalizumab
- DRUG Oleclumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2026-09 |
| Est. Completion | 2029-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07146230
The ClinicalTrials.gov registry entry for NCT07146230 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Radiotherapy is the first listed.
NCT07146230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07146230 about?
NCT07146230 is a clinical study titled "The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2". This is a randomized trial evaluating the efficacy and safety of sequential dual-agent immunotherapy and risk-adapted radiotherapy for patients with locally advanced non-small cell lung cancer (NSCLC) with a PD-L1 tumor proportion score of at least 50%. Participants will be randomized between two du...
What is the current status of trial NCT07146230?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2026-09. Estimated completion is 2029-02.
What interventions are being tested in trial NCT07146230?
The interventions under investigation include: Radiotherapy (RADIATION), Durvalumab (DRUG), Monalizumab (DRUG), Oleclumab (DRUG).
Who is sponsoring clinical trial NCT07146230?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.